Nastech Seeks Partner For MASCT Test To Compete Against Ductal Lavage
This article was originally published in The Gray Sheet
Executive Summary
Nastech Pharmaceutical is seeking a licensing partner or buyer for its Mammary Aspiration Specimen Cytology Test (MASCT), which the firm is touting as an alternative to ductal lavage and a potential early detector of breast cancer